Rising Pharmaceuticals

What Rising Pharmaceuticals does

Rising Pharmaceuticals, operating as Rising Pharma Holdings, Inc., is a US-based privately held pharmaceutical company headquartered in East Brunswick, New Jersey, with a regional hub in Hyderabad, India. Founded in 2019, the company markets and distributes generic pharmaceuticals across the United States through three operating units: Rising Pharmaceuticals (prescription generics, 250+ products), Rising Health (over-the-counter products, 52+ commercialized with 18 in the pipeline), and Casper Pharma (specialty pharmaceuticals in cardiovascular, gastrointestinal, urological, pain management, and ophthalmic markets).

The company's technical capabilities center on complex generics — sustained-release formulations, injectables, ophthalmics, and combination therapies — together with 505(b)(2) NDA products and a niche-generics strategy targeting underserved therapeutic areas. Manufacturing is conducted at USFDA-approved GMP facilities via a network of partners including India-based Inventia Healthcare and Laurus Labs, supported by an in-house R&D division offering formulation development, advanced analytical and in-vitro testing (polymorphism, microscopy, thermal analysis, IVRT), stability testing, bioequivalence and PBPK modeling, and a dedicated data management function using AI tools for compliance and traceability. A new sterile dosage facility opened in September 2023 expanded injectable and ophthalmic capacity.

Rising generates revenue through B2B distribution of prescription generics and OTC products to retail and independent pharmacies, wholesale distributors, and e-commerce channels, with prices negotiated through pharmacy benefit managers, insurance plans, and wholesale buyers rather than publicly disclosed. Strategic growth is concentrated in higher-complexity generics, specialty injectables (including the Edetate Calcium Disodium Injection launched in 2023 and commercially available from September 2024), and US supply chain reinforcement — though the June 2025 FDA Class II recall of 11,460 bottles of chlorthalidone 25mg tablets highlights ongoing regulatory and quality execution risk.

Name

Rising Pharmaceuticals

Legal name

Rising Pharma Holdings, Inc.

Website

https://risingpharma.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

251–500 employees

Short description

Rising Pharmaceuticals is a US-based privately held generic pharmaceutical distributor that markets prescription generics (250+ products), OTC products (52+ products), and specialty pharmaceuticals across cardiovascular, GI, urological, pain management, and ophthalmic markets, serving retail pharmacies, wholesalers, and e-commerce channels.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Ophthalmology Pharmaceuticals (HLAIAAAL), Ophthalmic & Otic Generics (HLAIABAF), Specialty Care Pharmaceuticals (HLAIAAAB), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Generic pharmaceuticals
• Prescription drug distribution
• Over-the-counter medications
• Specialty pharmaceuticals
• Complex generic formulations

Headquarters

HQ city

East Brunswick

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Generic Pharmaceuticals: Rising Pharmaceuticals markets and distributes prescription generic drugs across multiple therapeutic areas and dosage forms through a network of over 250 commercialized products, generating revenue from sales to pharmacies and healthcare providers in the US market.
2. Over-the-Counter (OTC) Pharmaceuticals: Rising Health markets and distributes generic OTC pharmaceutical products covering various therapies and dosage forms through retail and e-commerce channels, with a portfolio of over 52 products and 18 in the pipeline.
3. Specialty Pharmaceuticals: Casper Pharma focuses on specialty pharmaceutical products for cardiovascular, gastrointestinal, urological, pain management, and ophthalmic markets, leveraging a global network for development, acquisition, and commercialization.
4. Specialty Injectables and Ophthalmics: Revenue from sterile dosage capabilities including injectable and ophthalmic products, following the 2023 opening of a new manufacturing facility to bolster US supply chain.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Rising Pharmaceuticals develops, manufactures, and distributes a versatile portfolio of generic pharmaceutical products in the US market across three business units: Rising Pharmaceuticals (prescription generics with 250+ products in tablets, capsules, oral suspensions, and injectables), Rising Health (OTC products with 52+ products across anti-allergy, antacids, probiotics, laxatives, dietary supplements, pain management, and smoking cessation), and Casper Pharma (specialty pharmaceuticals in cardiovascular, GI, urological, pain management, and ophthalmic markets). The company focuses on niche and complex generics including sustained-release formulations, injectables, ophthalmic products, combination therapies, and 505(b)(2) NDA products, all manufactured at USFDA-approved GMP-compliant facilities.

Product overview

Rising Pharmaceuticals is organized as a platform company with three distinct business units operating under Rising Pharma Holdings, Inc. The core business consists of Rising Pharmaceuticals (prescription generics, the primary unit with 250+ products), Rising Health (OTC products, a fast-growing segment with 52+ products and 18 in pipeline), and Casper Pharma (specialty pharmaceuticals focusing on cardiovascular, GI, urological, pain management, and ophthalmic markets). The company also maintains a dedicated R&D division that supports all business units with formulation development, analytical testing, regulatory affairs, and clinical trial capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• Rising Pharmaceuticals: Core prescription generics business unit delivering high-quality prescription generics in multiple dosage forms.
• Rising Health
• Casper Pharma

Products and services

• Rising Pharmaceuticals (Prescription Generics) Rising Pharmaceuticals is the core prescription generics business unit offering a versatile portfolio of high-quality prescription generics in multiple dosage forms, including tablets, capsules, oral suspensions, and injectables, catering to diverse therapeutic needs. With over 250 products, it represents the company's primary business focus serving pharmacies, healthcare providers, and patients across the United States.
• Rising Health (OTC Products) Rising Health is the fast-growing over-the-counter (OTC) wing of Rising Pharmaceuticals, marketing and distributing generic OTC pharmaceutical products covering a variety of therapies and dosage forms through retail and e-commerce channels. The portfolio includes over 52 products across anti-allergy, antiemetics, antacids, probiotics, laxatives, dietary supplements, pain management, and smoking cessation categories, with 18 products in the pipeline.
• Casper Pharma (Specialty Pharmaceuticals) Casper Pharma is an emerging specialty pharmaceutical company focused on improving patients' lives by fulfilling medical needs in the cardiovascular, gastrointestinal, urological, pain management, and ophthalmic markets. The specialty product portfolio includes Aquasol A Parenteral, Fexmid (Cyclobenzaprine), Furadantin (Nitrofurantoin), Thalitone (Chlorthalidone), Triglide (Fenofibrate), and Zyloprim (Allopurinol).
• Edetate Calcium Disodium Injection Edetate Calcium Disodium Injection is an antidote treatment to address lead poisoning, commercially available in the United States. It expands the company's sterile injectable portfolio for lead poisoning treatment and represents an entry into the lead poisoning antidote market.

Quantifiable outcome

• Over 250 products commercialized with a robust pipeline of upcoming complex products.
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Edetate Calcium Disodium Injection (US Market)coreChannel Partner/ Reseller/ Distributor · 11 September 2024Rising Pharmaceuticals announced commercial availability of Edetate Calcium Disodium injection in the United States in September 2024, expanding their sterile injectable portfolio for lead poisoning treatment.
• CMO Partners (Contract Manufacturing Organizations)coreTechnology or Integration · 19 September 2023Rising Pharmaceuticals opened a new facility in September 2023 to bolster US supply chain by expanding sterile dosage capabilities including injectables and ophthalmics. The company works with certified manufacturing partners for product supply. All products can be tailored for market-specific needs.
• Phase 2 Clinical Trial of Chloroquine PhosphateminorStrategic or Co-development Partner · 20 May 2020Rising Pharmaceuticals supported a Phase 2 clinical trial of Chloroquine Phosphate for prophylaxis against COVID-19 in healthcare workers at risk for COVID-19, providing pharmaceutical products and supply chain support for the trial.
• CROWN Collaborative / Washington University School of MedicineminorStrategic or Co-development Partner · 18 May 2020Rising Pharmaceuticals supported a global clinical trial conducted by the CROWN Collaborative, represented by Washington University School of Medicine in the US, investigating an innovative approach to protecting essential healthcare workers. Rising provided pharmaceutical support for the clinical trial.
• Laurus LabscoreStrategic or Co-development Partner · 7 May 2020Rising Pharmaceuticals & Laurus Labs jointly supported a Phase 2 Randomized Clinical Trial of Hydroxychloroquine for Prophylaxis Against COVID-19 in Patients Receiving Cancer Therapy. This partnership combined Rising's pharmaceutical distribution capabilities with Laurus Labs' development and manufacturing expertise for clinical trial supply.
• Inventia Healthcare LimitedcoreTechnology or IntegrationInventia Healthcare Limited, an India-based pharmaceutical manufacturer, produces chlorthalidone blood pressure tablets for Rising Pharma Holdings, which then distributes the products in the United States. This is a manufacturing partnership where Inventia manufactures and Rising distributes finished pharmaceutical products. Products are subject to USFDA quality standards.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Glenmark Pharmaceuticals: Glenmark operates a US generics and specialty franchise with exposure to dermatology, respiratory, and oncology, sharing Rising's India-headquartered R&D model and US pharmacy distribution approach.
• Lannett Company: Lannett is a US-focused generic pharmaceutical manufacturer and distributor with a broad portfolio of oral solids, injectables, and specialty generics, making it one of the closest direct comparables to Rising's three-unit Rx, OTC, and specialty model.
• Dr. Reddy's Laboratories: Dr. Reddy's is a major India-based pharmaceutical company with a substantial US generics business covering oral solids, injectables, and specialty products, comparable to Rising on India-to-US manufacturing and broad Rx portfolio.
• Zydus Pharmaceuticals USA: Zydus's US arm markets a broad portfolio of generic and specialty pharmaceuticals across dosage forms, with India-based manufacturing — directly comparable to Rising's reliance on Indian CMOs and nationwide US pharmacy distribution.
• Amneal Pharmaceuticals: Amneal is a US-headquartered generic and specialty pharmaceutical company with deep exposure to oral solids, injectables, and complex generics, competing head-to-head with Rising across prescription generics and specialty segments like CNS and ophthalmology.
• Alembic Pharmaceuticals: Alembic is an India-based generic manufacturer with a growing US generics business spanning oral solids and select specialty areas, similar in scale, manufacturing footprint, and product breadth to Rising's portfolio.
• Aurobindo Pharma USA: Aurobindo's US subsidiary is one of the largest suppliers of oral generic pharmaceuticals in the United States, with a portfolio, channel mix, and India-manufacturing base that closely mirrors Rising's vertically integrated generic model.
• Apotex: Apotex is a Canada-headquartered global generic manufacturer with significant US presence across oral solids, injectables, and specialty generics, making it a strong comparable on portfolio breadth and pricing dynamics.

Broad incumbents

• Endo International (Par Pharmaceutical): Endo's Par Pharmaceutical generics franchise is one of the largest US generic players with deep pharmacy channel relationships and broad therapeutic coverage, serving as a broad incumbent benchmark for Rising's Rx generics scale and economics.
• Teva Pharmaceutical Industries: Teva is the world's largest generic drug manufacturer with extensive US generics, injectables, and specialty exposure; relevant as a broad incumbent setting the competitive ceiling on pricing and formulary access for mid-sized players like Rising.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rising Pharmaceuticals